Shitara, K., Park, H., Bekaii-Saab, T., Kim, S. S., Kamath, S., Pishvaian, M. J., … Strickler, J. H. (2022). MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers. In Annals of Oncology (Vol. 33, pp. S502–S502). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.05.183

Shitara, Kohei, Haeseong Park, Tanios Bekaii-Saab, Sunnie S. Kim, Suneel Kamath, Michael J. Pishvaian, Christopher Chen, et al. “MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers.” In Annals of Oncology, 33:S502–S502. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.05.183.

Shitara K, Park H, Bekaii-Saab T, Kim SS, Kamath S, Pishvaian MJ, et al. MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers. In: Annals of Oncology. Elsevier BV; 2022. p. S502–S502.

Shitara, Kohei, et al. “MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S502–S502. Crossref, doi:10.1016/j.annonc.2022.05.183.

Shitara K, Park H, Bekaii-Saab T, Kim SS, Kamath S, Pishvaian MJ, Chen C, Zhen DB, Mayor J, Tan Q, Strickler JH. MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers. Annals of Oncology. Elsevier BV; 2022. p. S502–S502.